Efficacy and Safety of Immunosuppressive Therapy for PBC–AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study

Table 4

Response to treatment in AIH features after 3, 6, and 12 months of therapy.

Variables	Overall (n=28, %)	UDCA-only group (n=14), %	UDCA+IS group (n=14), %	P value
3-month remission	4(14.2%)	0(0%)	4(28.6%)	0.098
6-month remission	6(21.4%)	1(7.1%)	5(35.7%)	0.165
12-month remission	7(33.3%)^#	1(9.1%)^##	6(60.0%)	0.024

Twenty-one patients were treated for more than 12 months in total.
^#Eleven patients were treated for more than 12 months in the UDCA-only group.
^##Ten patients were treated for more than 12 months in the UDCA+IS group.